LINC02372: A Potential Drug Target and Biomarker (G440117)

Target Name: LINC02372

NCBI ID: G440117

LINC02372

Other Name(s): Long intergenic non-protein coding RNA 2372 | long intergenic non-protein coding RNA 2372

LINC02372: A Potential Drug Target and Biomarker

Introduction

LINC02372 is a long intergenic non-protein coding RNA (lncRNA) molecule that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is located between the 5' and 3' ends of the genes encoding proteins , belongs to the long non-coding RNA (lncRNA) family. lncRNA molecules play an important role in various physiological processes such as gene expression regulation, chromatin remodeling, cell cycle regulation, apoptosis, immune response, metabolism and signal transduction.

Mechanism of action of LINC02372

LINC02372 plays an important role in cell cycle regulation. During G1 phase, LINC02372 binds to the nucleolus, thereby inhibiting rRNA synthesis. During S phase, LINC02372 inhibits DNA replication by binding to DNA-binding proteins. During the G2 phase, LINC02372 inhibits spindle formation by binding to tubulin. These results enable LINC02372 to play different roles in different stages of the cell cycle.

The role of LINC02372 in immune response

LINC02372 plays an important role in immune response. Studies have shown that LINC02372 can regulate T cell fate decisions. Under antigen stimulation, LINC02372 can regulate the activity of CDK4 and CDK6, thereby affecting the proliferation and differentiation of T cells. In addition, LINC02372 can also regulate the expression of PD-L1, thereby affecting the immunogenicity of T cells.

The role of LINC02372 in metabolism

LINC02372 also plays an important role in metabolism. Research shows that LINC02372 can regulate glucose metabolism. In the liver, LINC02372 can bind glucose in the liver, thereby affecting glucose absorption and utilization. In addition, LINC02372 can also regulate fat metabolism, thereby affecting the synthesis and breakdown of fat.

LINC02372 as a drug target

LINC02372 plays an important role in a variety of physiological processes and is therefore considered a potential drug target. Currently, studies have shown that LINC02372 can be used as a drug target for the treatment of cancer. For example, LINC02372 can be used as a drug target for the treatment of liver cancer. By inhibiting the effect of LINC02372, the survival rate of liver cancer patients can be improved. In addition, LINC02372 can also be used as a drug target to treat other cancers, such as lung cancer, breast cancer, etc.

LINC02372 as a biomarker

LINC02372 can also serve as a biomarker. Research shows that LINC02372 can be used as a biomarker for the treatment of gastric cancer. By detecting the expression level of LINC02372, the survival rate of gastric cancer patients can be predicted. In addition, LINC02372 can also be used as a biomarker for other diseases, such as lung cancer, diabetes, etc.

in conclusion

LINC02372 is a lncRNA molecule that plays an important role in various physiological processes such as cell cycle regulation, immune response, metabolism and signal transduction. It is a potential drug target, cancer treatment and biomarker. In the future, researchers will continue to study the role of LINC02372 in the treatment of cancer and immune response, hoping to bring more hope to human health.

Protein Name: Long Intergenic Non-protein Coding RNA 2372

The "LINC02372 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02372 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets